Long-Term Results of Kidney Transplantation With Cyclosporine- and Everolimus-Based Immunosuppression

Transplantation Proceedings

Volumn 38, Issue 4, 2006, Pages 1018-1019

  Iaria, G ^a   Pisani, F ^b   Iorio, B ^a   Lucchesi, C ^a   De Luca, L ^a   Ielpo, B ^a   D'Andria, D ^a   Tariciotti, L ^a   Tisone, G ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; CORTICOSTEROID; CYCLOSPORIN A; EVEROLIMUS; LIPID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TACROLIMUS;

ADULT; AGED; ARTHRALGIA; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CYTOMEGALOVIRUS INFECTION; DIALYSIS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; FEMALE; FOLLOW UP; GRAFT SURVIVAL; HUMAN; HYPERLIPIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIPID BLOOD LEVEL; LONG TERM CARE; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RENAL GRAFT DYSFUNCTION; STAINING; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; CYCLOSPORINE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; SIROLIMUS; TIME FACTORS;

EID: 33744786507     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2006.04.001     Document Type: Article

References (3)

1. Pascual J., Marcen R., and Ortuno J. Clinical experience with everolimus (Certican). optimizing dose and tolerability. Transplantation 79 9 Suppl (2005) S80
2. Lorber M.I., Ponticelli C., Whelchel J., et al. Therapeutic drug monitoring for everolimus in kidney transplantation using 12-month exposure, efficacy, and safety data. Clin Transplant 19 (2005) 145
3. Montagnino G., Sandrini S., Casciani C., et al. A randomized trial of steroid avoidance in renal transplant patients treated with everolimus and cyclosporine. Transplant Proc 37 (2005) 788